SynGenSys creates product-specific libraries of synthetic genetic parts for next-generation biomedicines.
SynGenSys has raised $2.3M in total funding. The most recent round was Seed. The last funding was announced in April 2024.
SynGenSys's investors include Translink.
SynGenSys is headquartered in Sheffield, United Kingdom.
SynGenSys creates product-specific libraries of synthetic genetic parts for next-generation biomedicines.
SynGenSys is at the Seed stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"SynGenSys — Funding & Investors." VCBacked, April 4, 2024, https://www.vcbacked.co/company/syngensys. Accessed August 1, 2026.
VCBacked. (2024). SynGenSys — Funding & Investors. Retrieved August 1, 2026, from https://www.vcbacked.co/company/syngensys
{{cite web |title=SynGenSys — Funding & Investors |url=https://www.vcbacked.co/company/syngensys |website=VCBacked |access-date=August 1, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated